| Name | BRD73954 |
| Description | BRD73954, an effective and specific HDAC inhibitor, which is with IC50 of 36 nM and 120 nM for HDAC6 and HDAC8, respectively. |
| In vitro | As compared to the other class I and II histone deacetylases (HDACs) (HDAC1, 12 μM; HDAC2, 9 μM; HDAC3, 23 μM; HDAC4, >33 μM; HDAC5, >33 μM; HDAC7, 13 μM; HDAC8, 120 nM; HDAC9, >33 μM), BRD73954 maintains excellent selectivity toward HDAC6 and HDAC8 with IC50 of 36 nM and 120 nM, respectively. Treatment with BRD73954 results in a robust increase in α -tubulin acetylation. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 5.7 mg/mL (20.05 mM), Heating is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (7.03 mM), Sonication is recommended. DMSO : 16.67 mg/mL (58.63 mM), Sonication is recommended.
|
| Keywords | α-tubulin acetylation | Inhibitor | inhibit | Histone deacetylases | HeLa cells | HDAC8 | HDAC6 | HDAC4 | HDAC2 | HDAC | H3 acetylation | BRD-73954 | BRD73954 | BRD 73954 | Ac-Tubulin |
| Inhibitors Related | Panobinostat | Theophylline monohydrate | Valproic acid sodium salt | Methoxyacetic acid | Sodium 4-phenylbutyrate | Acefylline | Manganese chloride (tetrahydrate) | Curcumin | Valproic Acid | Sodium butanoate | 4-Phenylbutyric acid | Theophylline |
| Related Compound Libraries | Reprogramming Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Cancer Cell Differentiation Compound Library | Epigenetics Compound Library | HIF-1 Signaling Pathway Compound Library | Hematonosis Compound Library | Inhibitor Library | NO PAINS Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library |